Clinical trial
Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
NCT02776813 is registered in ClinicalTrials.gov with Cogent Biosciences, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 1 Study of ACTR087, Autologous T Lymphocytes Expressing Antibody Coupled T-cell Receptors (CD16V-41BB-CD3ζ), in Combination With Rituximab, in Subjects With Relapsed or Refractory CD20-Positive B-Cell Lymphoma
- Lead sponsor
- Cogent Biosciences, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 31, 2016
- Completion date
- February 12, 2020
- Enrollment
- 34 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.